However, the popular anti-inflammatory drug was linked to at least one other clinical benefit cardiologists should know about. 

Anne Kroman, DO, PhD, noted that early, aggressive treatment is critical when EP leads need to be removed. 

The two devices, already approved by the FDA, were designed with batteries expected to last more than 15 years. 

“We identified a problem in cardiology,” one cardiologist explained. “Heart imaging has made remarkable progress in recent decades, but the electrics of the heart have eluded us."

"The PulseSelect PFA system ushers the EP community to a new era of safe, effective and efficient AF ablation that overcomes many challenges in our current practice," said Amin Al-Ahmad, MD, St. David's Medical Center in Austin, Texas. 

The new study included data on patients who presented for TAVR with preexisting AFib as well as those who developed new-onset AFib after the procedure. 

According to Ajax Health CEO and industry veteran Duke Rohlen, the new company will be focused on offerings that "prioritize precision, simplicity and efficiency."

New AFib recommendations from the American College of Cardiology and American Heart Association covered significant ground—but there is still much more to learn, experts explained.